Bristol-Myers Squibb stock has delivered a 26.5% return over the past year, which puts fresh attention on whether the current price still offers value or if most of the easy gains are already in the rearview mirror.

• Over the last 12 months, Bristol-Myers Squibb has returned 26.5%, which means recent buyers have been rewarded and new investors now have to ask how much upside is left from here.
• The recent clinical collaboration in kidney cancer and progress with Camzyos may support expectations for future cash flows, while the US Medicare drug price negotiation changes and an ongoing House investigation into clinical trials in China can weigh on how investors price long term risk.
• The stock screens as undervalued on earnings-based multiples, yet a 4 out of 6 overall value score points to a mixed picture rather than a straightforward bargain or an obvious overpricing.

The issue now is whether Bristol-Myers Squibb's recent rerating has already captured most of that value or if the current valuation still leaves room for a reasonable margin of safety.

Is Bristol-Myers Squibb a Bargain on Earnings?

The P/E ratio fits Bristol-Myers Squibb well because earnings remain a key anchor for how investors value large pharmaceutical stocks. Right now, Bristol-Myers Squibb trades on a P/E of about 16.2x, which is close to the Pharmaceuticals industry average of 15.5x but below the peer group average of 27.3x.

The fair P/E ratio, which blends in the company’s margins, scale, risk profile and sector, is estimated at 19.2x. That is above the current 16.2x, indicating that the stock trades at a discount to what this framework implies for Bristol-Myers Squibb. Despite the recent Medicare pricing discussion and the House investigation into clinical trials in China, the market multiple still sits below this tailored fair value mark.

On this earnings multiple, Bristol-Myers Squibb stock currently appears undervalued relative to this framework.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bristol-Myers Squibb pick up where this valuation puzzle leaves off by spelling out which paths for Bristol-Myers Squibb's earnings, margins and growth would need to play out for the stock to be worth materially more or materially less than it is today, and they sit on Simply Wall St's Community page. Where a single ratio or model output gives one figure, these narratives outline the future that figure relies on so you can watch over time whether those expectations still line up with what the business is actually delivering.

The community sees Bristol-Myers Squibb in two very different lights, with one camp focused on pipeline depth and another on patent and pricing pressure.

Bull case: 9% undervalued

"Robust late-stage pipeline and ongoing life-cycle management for major brands, plus strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions…"

Bear case: 26% overvalued

"The impending loss of exclusivity for major blockbusters such as Eliquis, Opdivo, and Revlimid after 2026 will trigger severe revenue cliffs, as these high-margin drugs face a rapid influx of generics and biosimilars…"

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

The Bottom Line

On current P/E multiples, Bristol-Myers Squibb still screens as undervalued, but the broader valuation checks suggest this is not a simple mispricing. The tension between enthusiasm for the pipeline and concern over patent and pricing pressure is what really drives the gap between bull and bear views. For you, the key question is whether the current discount reflects an overly cautious market or a fair penalty for those legal, regulatory and patent risks. How convincingly Bristol-Myers Squibb can replace and defend its major cash flows will decide whether today’s valuation is an opportunity or a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.